Amphastar Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Amphastar Pharmaceuticals, Inc. (AMPH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $8.78 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-06
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-06-30 was $8.78, a 25.66% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $9.31, a 30.42% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-09-30 was $12.46.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-06-30 was $11.81, a 39.12% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $13.22, a 39.61% decline from fiscal 2024.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $21.89, a 30.61% increase from fiscal 2023.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $16.76, a 13.63% increase from fiscal 2022.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $14.75, a 93.57% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.78 10-Q · filed 2026-08-06 | $9.27 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $9.31 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $13.22 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $12.46 10-Q · filed 2025-11-06 | $13.22 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | $11.81 10-Q · filed 2026-08-06 | $13.25 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $13.38 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $21.89 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $21.89 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | $19.40 10-Q · filed 2025-08-07 | $21.89 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $22.16 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $16.76 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $21.49 10-Q · filed 2024-11-07 | $16.76 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $17.77 10-Q · filed 2024-08-09 | $16.76 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | $16.67 10-Q · filed 2024-05-10 | |||
| 2022-12-31 | $14.75 10-K · filed 2025-03-03 | |||
| 2022-09-30 | $14.40 10-Q · filed 2023-11-08 | $14.75 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | $12.13 10-Q · filed 2023-08-09 | $14.75 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $15.06 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $7.62 10-K · filed 2024-02-29 | |||
| 2021-09-30 | $8.00 10-Q · filed 2022-11-08 | $7.62 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $7.30 10-Q · filed 2022-08-09 | $7.60 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $7.66 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $5.51 10-K · filed 2023-03-01 | |||
| 2020-09-30 | $8.64 10-Q · filed 2021-11-09 | $5.50 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $7.15 10-Q · filed 2021-08-09 | $5.48 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $5.33 10-Q · filed 2021-05-07 | |||
| 2019-12-31 | $8.48 10-K · filed 2022-03-11 | |||
| 2019-09-30 | $9.50 10-Q · filed 2020-11-06 | $8.48 10-Q · filed 2020-11-06 | ||
| 2019-06-30 | $8.17 10-Q · filed 2020-08-07 | $8.46 10-Q · filed 2020-08-07 | ||
| 2019-03-31 | $8.49 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | $7.80 10-K · filed 2021-03-15 | |||
| 2018-09-30 | $7.90 10-Q · filed 2019-11-08 | $7.79 10-Q · filed 2019-11-08 | ||
| 2018-06-30 | $6.53 10-Q · filed 2019-08-09 | $7.79 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | $7.94 10-Q · filed 2019-05-10 | |||
| 2017-12-31 | $4.98 10-K · filed 2020-03-16 | |||
| 2017-09-30 | $6.23 10-Q · filed 2018-11-09 | $4.95 10-Q · filed 2018-11-09 | ||
| 2017-06-30 | $5.01 10-Q · filed 2018-08-09 | $4.92 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $4.87 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | $3.42 10-K · filed 2019-03-15 | |||
| 2016-09-30 | $6.34 10-Q · filed 2017-11-09 | $3.42 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | $3.88 10-Q · filed 2017-08-09 | $3.40 10-Q · filed 2017-08-09 | ||
| 2016-03-31 | $3.37 10-Q · filed 2017-05-10 | |||
| 2015-12-31 | $3.45 10-K · filed 2018-03-14 | |||
| 2015-09-30 | $4.54 10-Q · filed 2016-11-09 | $3.44 10-Q · filed 2016-11-09 | ||
| 2015-06-30 | $2.89 10-Q · filed 2016-08-09 | $3.44 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | $3.53 10-Q · filed 2016-05-10 | |||
| 2014-12-31 | $4.02 10-K · filed 2017-03-15 | |||
| 2014-09-30 | $4.02 10-Q · filed 2015-11-13 | |||
| 2014-06-30 | $5.33 10-Q · filed 2015-08-13 | $4.02 10-Q · filed 2015-08-13 | ||
| 2014-03-31 | $3.20 10-Q · filed 2015-05-14 | |||
| 2013-12-31 | $2.79 10-K · filed 2016-03-15 | |||
| 2013-09-30 | $2.50 10-Q · filed 2014-11-13 | $2.54 10-Q · filed 2014-11-13 | ||
| 2013-06-30 | $3.66 10-Q · filed 2014-08-13 | $3.66 10-Q · filed 2014-08-13 | ||
| 2012-12-31 | $3.01 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |